IP Library Granted Patent US 8,114,836
Granted Patent B2
US 8,114,836 · App. 12/401,755 · Granted Feb 14, 2012

Long-acting veterinary polypeptides and methods of producing and administering same

Assignee: Prolor Biotech Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,836
App. No.
12/401,755
Granted
Feb 14, 2012
Kind
B2
Abstract

A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.

Claims (16)

1. A polypeptide consisting of a non-human growth hormone polypeptide, one chorionic gonadotrophin carboxy terminal peptide attached to the amino terminus of said non-human growth hormone polypeptide, and two chorionic gonadotrophin carboxy terminal peptides attached to the carboxy terminus of said non-human growth hormone polypeptide.

2. The polypeptide of claim 1 , wherein the sequence of at least a single chorionic gonadotrophin carboxy terminal peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 17 and SEQ ID NO: 18.

3. The polypeptide of claim 1 , wherein at least a single chorionic gonadotrophin carboxy terminal peptide is truncated.

4. A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

5. A polypeptide consisting of a non-human growth hormone polypeptide, one chorionic gonadotrophin carboxy terminal peptide attached to the amino terminus of said non-human growth hormone polypeptide, two chorionic gonadotrophin carboxy terminal peptides attached to the carboxy terminus of said non-human growth hormone polypeptide, and a signal peptide attached to the amino terminus of said one chorionic gonadotrophin carboxy terminal peptide.

6. The polypeptide of claim 5 , wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19.

7. The polypeptide of claim 5 , wherein the sequence of at least a single chorionic gonadotropin carboxy terminal peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 17 and SEQ ID NO: 18.

8. The polypeptide of claim 5 , wherein at least a single chorionic gonadotrophin carboxy terminal peptide is truncated.

9. A composition comprising the polypeptide of claim 5 and a pharmaceutically acceptable carrier.

10. A method of extending the biological half life of a non-human growth hormone polypeptide, comprising the step of attaching one chorionic gonadotrophin carboxy terminal peptide to the amino terminus of said non-human growth hormone polypeptide and two chorionic gonadotrophin carboxy terminal peptides to the carboxy terminus of said non-human growth hormone polypeptide, thereby extending the biological half life of a non-human growth hormone polypeptide.

11. The method of claim 10 , wherein the sequence of at least a single chorionic gonadotrophin carboxy tei iiiinal peptide consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18.

12. The method of claim 10 , wherein at least a single chorionic gonadotrophin carboxy terminal peptide is truncated.

13. A method of extending the biological half life of a non-human growth hormone polypeptide, comprising the step of attaching one chorionic gonadotrophin carboxy terminal peptide to the amino terminus of said non-human growth hormone polypeptide and two chorionic gonadotrophin carboxy terminal peptides to the carboxy terminus of said non-human growth hormone polypeptide, and a signal peptide attached to the amino terminus of said one chorionic gonadotrophin carboxy terminal peptide, thereby extending the biological half life of a non-human growth hormone polypeptide.

14. The method of claim 13 , wherein the sequence of at least a single chorionic gonadotrophin carboxy terminal peptide consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18.

15. The method of claim 13 , wherein at least a single chorionic gonadotrophin carboxy terminal peptide is truncated.

16. The method of claim 13 , wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19.

Assignments (5)
CHANGE OF NAME Recorded May 23, 2014
From: PROLOR BIOTECH LTD.
To: OPKO BIOLOGICS LTD.
Reel/Frame 033015/0859 →
CHANGE OF NAME Recorded Mar 24, 2014
From: MODIGENETECH LTD.
To: PROLOR BIOTECH LTD.
Reel/Frame 032503/0737 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT RECEIVING PARTY DATA NAME: MODIGENE INC PREVIOUSLY RECORDED ON REEL 022596 FRAME 0364. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT RECEIVING PARTY DATA NAME: MODIGENETECH LTD.. Recorded Aug 12, 2013
From: FARES, FUAD; FIMA, UDI EYAL
To: MODIGENETECH LTD
Reel/Frame 031003/0358 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2011
From: FARES, FUAD; FIMA, UDI EYAL
To: PROLOR BIOTECH LTD.
Reel/Frame 027040/0275 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2009
From: FARES, FUAD; FIMA, UDI EYAL
To: MODIGENE INC
Reel/Frame 022596/0364 →
Continuity (3)
Continuation 11702156 · Feb 5, 2007
Provisional Application 60764761 · Feb 3, 2006
Related Publication 20090286733A1 · Nov 19, 2009